Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

Show other versions (1)

Purpose and Methods Our secondary analyses compared survival with eribulin versus capecitabine in various patient subgroups from a phase 3, open-label, randomized study. Eligible women aged ≥18 years with advanced/metastatic breast cancer and ≤3 prior chemotherapies (≤2 for advanced/metastatic disea...

Full description

Bibliographic Details
Main Authors: Chris Twelves, Ahmad Awada, Javier Cortes, Louise Yelle, Galina Velikova, Martin S. Olivo, James Song, Corina E. Dutcus, Peter A. Kaufman
Format: Article
Language:English
Published: SAGE Publishing 2016-01-01
Series:Breast Cancer: Basic and Clinical Research
Online Access:https://doi.org/10.4137/BCBCR.S39615

Internet

https://doi.org/10.4137/BCBCR.S39615

Similar Items